Metabolic Reprogramming in Chronic Kidney Disease Care

Abstract

Chronic kidney disease (CKD) is a progressive condition characterized by the gradual loss of renal function, intricately linked with profound metabolic disturbances. Recent advances in molecular nephrology have elucidated key mechanisms of metabolic reprogramming underpinning CKD pathogenesis and progression. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical presentation, diagnostic strategies, and therapeutic interventions targeting metabolic pathways in CKD care, with an emphasis on clinical applicability, recent research findings, and guideline-based recommendations for healthcare professionals. Understanding the dynamic interplay between metabolic derangements and kidney function is essential for optimizing CKD management and improving patient outcomes.

Introduction

CKD affects approximately 10% of the global population and represents a major public health concern due to its association with increased morbidity, mortality, and healthcare burden. The recognition of metabolic reprogramming an adaptive and maladaptive alteration in cellular metabolism as a central feature of CKD has shifted paradigms in both research and clinical management. This article aims to provide a comprehensive review of the mechanisms, clinical implications, and emerging interventions related to metabolic reprogramming in CKD, tailored for nephrologists, internists, and allied healthcare professionals.

Epidemiology / Disease Burden

CKD is estimated to affect over 850 million individuals worldwide, with a rising prevalence driven by aging populations, diabetes, hypertension, and obesity. The burden of CKD extends beyond renal dysfunction to encompass cardiovascular disease, mineral bone disorders, and metabolic complications. According to the 2021 Global Burden of Disease Study, CKD is now the 12th leading cause of death globally. Early identification and management of metabolic disturbances are pivotal in mitigating disease progression and complications.

Pathophysiology

Metabolic reprogramming in CKD involves complex alterations in glucose, lipid, protein, and energy metabolism. Mitochondrial dysfunction, oxidative stress, and impaired fatty acid oxidation are hallmark features. Uremic toxins, such as indoxyl sulfate and p-cresyl sulfate, further disrupt metabolic homeostasis by inhibiting cellular respiration and promoting inflammation. The kidney’s role as a metabolic organ is compromised, leading to insulin resistance, dyslipidemia, and metabolic acidosis. Moreover, altered signaling through pathways such as AMPK, mTOR, and HIF-1α contributes to maladaptive responses in renal parenchymal and immune cells, exacerbating fibrosis and loss of nephron mass.

Risk Factors

Traditional risk factors for CKD-related metabolic reprogramming include diabetes mellitus, hypertension, older age, obesity, and genetic predisposition. Non-traditional risk factors, such as chronic inflammation, oxidative stress, and disturbances in gut microbiota, also modulate metabolic pathways and influence CKD progression. Recent research highlights the role of dietary patterns, physical inactivity, and exposure to environmental toxins in shaping metabolic risk profiles among CKD patients.

Clinical Features

Patients with CKD often present with a spectrum of metabolic abnormalities including hyperglycemia, hyperlipidemia, sarcopenia, and metabolic acidosis. These features may manifest as fatigue, muscle wasting, anorexia, and cardiovascular symptoms. Advanced CKD is associated with cachexia, impaired glucose tolerance, and increased susceptibility to infections. Recognizing these clinical phenotypes is essential for timely intervention and prevention of complications.

Diagnosis

Diagnosis of metabolic reprogramming in CKD relies on a combination of laboratory, imaging, and clinical assessments. Key investigations include serum creatinine, estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio, fasting glucose, glycated hemoglobin (HbA1c), lipid profile, and markers of acid-base balance. Emerging biomarkers such as fibroblast growth factor 23 (FGF23), adiponectin, and circulating mitochondrial DNA are under investigation for their utility in early detection and risk stratification. Imaging modalities, including dual-energy X-ray absorptiometry (DEXA), assist in evaluating muscle mass and bone metabolism.

Treatment & Management

Current CKD management strategies focus on addressing both renal and metabolic derangements. Glycemic control with sodium-glucose cotransporter 2 (SGLT2) inhibitors, renin-angiotensin-aldosterone system (RAAS) blockade, and tailored dietary interventions are foundational. Correction of metabolic acidosis with oral bicarbonate, lipid-lowering therapy, and optimization of protein intake are recommended. Exercise and physical rehabilitation programs help counteract sarcopenia and improve metabolic fitness. Multidisciplinary care involving nephrologists, dietitians, and endocrinologists is critical for comprehensive management.

Recent Advances / Emerging Therapies

Recent advances have focused on novel agents targeting metabolic pathways. SGLT2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists demonstrate renoprotective and metabolic benefits, independent of glycemic effects. Agents modulating mitochondrial function, such as bardoxolone methyl, and anti-inflammatory strategies using Nrf2 activators are under clinical evaluation. Gut microbiota modulation through prebiotics, probiotics, and symbiotics represents a promising adjunct to traditional therapies. Personalized medicine approaches, leveraging omics data and machine learning, are poised to refine risk stratification and therapeutic targeting in metabolic reprogramming.

Guideline Recommendations

International guidelines from KDIGO and the American Diabetes Association emphasize the importance of individualized metabolic management in CKD. Key recommendations include early screening for metabolic disturbances, integrated risk factor modification, and the use of SGLT2 inhibitors in eligible patients. Dietary sodium restriction, physical activity, and correction of metabolic acidosis are endorsed. Guideline updates increasingly reflect the role of metabolic reprogramming in CKD progression and advocate for multidisciplinary, patient-centered care models

Conclusion

Metabolic reprogramming is a central feature in the pathogenesis and progression of CKD, impacting clinical outcomes and therapeutic strategies. Recent insights into the mechanisms of metabolic alteration have informed the development of novel interventions and refined clinical practice guidelines. Early recognition and targeted management of metabolic derangements are essential for improving prognosis and quality of life in CKD patients. Ongoing research into emerging therapies and precision medicine holds promise for further advancements in CKD care.